Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant SARS-CoV-2 vaccine (CHO cell) in healthy people aged 3 years and older
NCT04869592Phase 2Completed
- Sponsor
- Serum Institute of India
- Start
- Apr 2021
- Primary completion
- Aug 2023
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of MVC-COV1901 in coronavirus disease 2019 (COVID-19), sponsored by Serum Institute of India. Started Apr 2021; status: completed.
02
Drugs
MVC-COV1901
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04869592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04869592.